Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer

Table 1 An overview of cf-DNA in ovarian cancer patients

cf-DNA	Year	Sample Type	NO. Patients	Targeted gene	Diagnosis	Prognosis	Response to therapy	Reference
DNA amount	2015	Serum	36	–	√	–	–	[24]
	2014	Plasma	144	Cyclophilin A	–	√	–	[30]
	2010	Plasma	164	GAPDH, beta-actin	–	√	–	[84]
Reversion mutation	2017	Plasma	19	BRCA1, BRCA2, TP53	–	–	√	[85]
	2017	Plasma	30	BRCA1, BRCA2, TP53	–	–	√	[86]
Somatic mutation	2014	Plasma/serum	1	FGFR2-FAM76A	√	–	–	[87]
	2012	Plasma	15	KRAS, PIK3CA, H1047R	√	√	–	[36]
	2008	Plasma	119	p53	√	–	–	[88]
	2005	Plasma/serum	69	TP53	–	√	–	[89]
Aberrant methylation	2017	Serum	114	RUNX3, TFPI2, OPCML	√	–	–	[90]
	2009	Plasma	33	BRCA1, HIC1, PAX5, PGR-PROX, THBS1	√	–	–	[91]
	2005	Plasma	51	RASSF1A	√	√	–	[92]
	2004	Peritoneal fluids	57	Panel genes including: TIMP3, CDH1, APC, ESR1, BRCA1, MYOD1, GSTM3, TITF1	√	√	–	[93]
Chromosomal abnormality	2017	Plasma	57	–	√	–	–	[27]
	2002	Serum	38	–	√	√	–	[94]
	2001	Serum	30	p53	√	√	–	[95]

ISSN: 1757-2215